Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Miami Beach, Florida Clinical Trials

A listing of Miami Beach, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (47) clinical trials

Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.

Eighty (80) subjects fulfilling all inclusion/exclusion criteria's will be randomly assigned to receive allogeneic hMSCs or placebo in a 1:1 blinded fashion. Forty (40) subjects will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion. ...

Phase

4.56 miles

Learn More »

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

In this Study, cells administered via intravenous infusion (IV) will be tested in 37 patients in two phases (Pilot and Randomized): The pilot phase will consist of 12 subjects and the randomized phase will consist of 25 subjects. Subjects in each pilot phase group (Group 1, 2, 3 and 4) ...

Phase

4.56 miles

Learn More »

Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects

This will be a single-blinded, vehicle-controlled randomized study in healthy controls to test the efficacy of the topical gel formulation with three differing concentrations of acetaminophen (APAP) for itch relief. To detect medium effects of the treatments with a given of 0.5 and an error probability of 0.05, with a ...

Phase

4.56 miles

Learn More »

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

This study will be conducted in 2 phases. Phase 1 evaluates AST-008 given in combination with pembrolizumab in patients with advanced solid tumors in a classical 3+3 dose escalation design, with up to five ascending dose cohorts of AST-008 and enrollment of 3 patients per cohort to identify an RP2D. ...

Phase

4.56 miles

Learn More »

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

The impact of Type 1 Diabetes. In the U.S. alone, approximately 1.3 million people, including children and adolescents, suffer from type 1 diabetes (T1D); the disease incidence is increasing in many countries, also in children and adolescents. Chronic autoimmune T cell responses against pancreatic -cells are considered the primary cause ...

Phase

4.56 miles

Learn More »

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent Resectable Osteosarcoma

Treatment will be administered in 28 day cycles with the first cycle in the neoadjuvant setting. This will be followed by surgery to render the participant in surgical remission. Subsequently the participant will continue to receive treatment for up to 12 additional cycles or until recurrence, whichever occurs first. For ...

Phase

4.56 miles

Learn More »

Single Ascending Dose Study in Participants With LCA10

This is an open-label, single ascending dose study of AGN-151587 (EDIT-101) in adult and pediatric (ie, ages 3 to 17) participants with LCA10-IVS26. Approximately 18 participants will be enrolled in up to 5 cohorts to evaluate up to 3 dose levels of AGN-151587 in this study. AGN-151587 is a novel ...

Phase

4.56 miles

Learn More »

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

This is a multicenter, open-label, single-arm phase 1b/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic EBV+ NPC. Tabelecleucel will be selected for each subject from the bank of available tabelecleucel cell products based on matching 2 ...

Phase

4.56 miles

Learn More »

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. This is a Phase 1/2, open label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical study to evaluate the safety and tolerability, biodistribution, shedding, and preliminary ...

Phase

4.56 miles

Learn More »

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Phase

4.56 miles

Learn More »